BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 18833073)

  • 1. Biological agents in the treatment of psoriasis.
    Tzu J; Krulig E; Cardenas V; Kerdel FA
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG; Gupta AK; Cherman AM; Inniss KA
    J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
    Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of biologic treatments for psoriasis with emphasis on infliximab.
    Pirzada S; Tomi Z; Gulliver W
    Skin Therapy Lett; 2007 Apr; 12(3):1-4. PubMed ID: 17487347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
    J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic agents in the treatment of psoriasis.
    Guarneri F; Guarneri C; Guarneri B
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):193-217. PubMed ID: 19075983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologicals in the treatment of psoriasis.
    Boker A; Kimball AB; Rolz-Cruz G
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
    Clark L; Lebwohl M
    J Am Acad Dermatol; 2008 Mar; 58(3):443-6. PubMed ID: 18083274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the mechanisms and efficacy of biological therapies for psoriasis.
    Koo J; Khera P
    J Dermatol Sci; 2005 May; 38(2):75-87. PubMed ID: 15862940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapies in psoriasis: a new therapeutic approach.
    Gisondi P; Girolomoni G
    Autoimmun Rev; 2007 Sep; 6(8):515-9. PubMed ID: 17854741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
    Saini R; Tutrone WD; Weinberg JM
    Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biologics in the treatment of psoriasis].
    Dissemond J; Grabbe S
    MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer treatment options for patients with moderate-to-severe psoriatic disease.
    Roebuck HL
    Nurse Pract; 2006 Aug; 31(8):5-6,11. PubMed ID: 16966969
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.